Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.
PMID: 9359746
1997
The Journal of infectious diseases
Abstract: Replication of zidovudine-resistant human immunodeficiency virus type 1 (HIV-1) strains (containing the 41 Met-->Leu and 215 Thr-->Tyr mutations in reverse transcriptase [RT]) was inhibited to a significantly greater extent by the combination of lamivudine and quinoxaline HBY 097 than by either drug alone or even fully suppressed by concomitant HBY 097 and lamivudine administration at relatively low concentrations.
Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.
PMID: 8624762
1996
Journal of acquired immune deficiency syndromes and human retrovirology
Abstract: In p87, K70R also appeared at 4 months, but T215Y and K219Q were not observed until 18 months and M41L not at all.
Abstract: In patient p74, K70R appeared after 4 months, T215Y at 5.5 months, and M41L at 13 months.
Abstract: The evolution of the viral population in that patient was dominated by the unique appearance of T215Y and subsequently M41L, with all sequences from the last time point being descended by a single path from the pretreatment samples.
Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
Abstract: Highly PFA-resistant HIV- 1 strains were hypersusceptible to AZT; conversely, AZT-resistant strains with M41L and T215Y; M41L, L210W, and T215Y; or M41L, D67N, K70R, and T215Y mutations were 2.2- to 2.5-fold hypersusceptible to PFA.
Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
PMID: 7594706
1995
The Journal of infectious diseases
Abstract: However, after prolonged ddI monotherapy, mutations associated with zidovudine resistance (M41L, D67N, K70R, and/or T215Y) were detected in HIV-1 isolates from both patients.
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.
PMID: 7509370
1994
The Journal of general virology
Abstract: High level resistance to 3'-azido-3'-deoxythymidine (AZT, zidovudine or Retrovir) is conferred by the presence of four or five mutations (Met-41-->Leu; Asp-67-->Asn; Lys-70-->Arg; Thr-215-->Tyr or Phe; Lys-219-->Gln) in the human immunodeficiency virus (HIV) reverse transcriptase.
Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.
Abstract: The Thr-215-->Phe virus was less AZT resistant than the Thr-215-->Tyr mutant, both on its own and when each was combined with the Met-41-->Leu mutant.
HIV mutation literature information.
PMID: 
1997
The Journal of infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT